• Versus Systems operates a patented rewards platform that combines gamification with real-world prizes to increase audience engagement and customer loyalty.
• The company’s technology has been used by more than 10 million consumers and deployed alongside major sports, entertainment and corporate brands.
• Its Winfinite platform enables brands to launch customizable interactive campaigns without extensive development resources.
• Versus is expanding across multiple engagement channels, including web, mobile, broadcast and live-event environments.
• The company’s Filter Fan Cam product creates interactive fan experiences and sponsorship opportunities at major sporting events and entertainment venues.
• Growing adoption of gamification technologies is creating a large market opportunity as companies seek new ways to improve customer engagement and retention.

One of the biggest challenges marketers face in the digital economy is capturing attention and holding it long enough to create meaningful customer relationships. Consumers today are exposed to thousands of advertisements, promotions and content experiences every day. As competition for attention intensifies, companies are increasingly turning toward interactive engagement strategies rather than traditional advertising alone. One of the fastest-growing approaches is gamification.

According to Versus Systems (NASDAQ: VS), a leading provider of gamification and audience engagement technology, 70% of millennials are more likely to engage with a brand when gamification is involved, while 60% of marketers report increased customer engagement and 55% report improved customer loyalty through gamified experiences.

Starting from the simple premise that audiences are more likely to engage when participation is rewarded, the company developed and operates a patented earned-rewards platform that enables brands, sports teams, broadcasters and content creators to embed games and real-world prizes directly into digital and live experiences.

Rather than asking consumers to passively consume content, the platform encourages participation through interactive challenges, contests and reward-based activities.

According to its corporate presentation, Versus has engaged more than 10 million consumers through campaigns deployed across sports, entertainment and corporate environments (https://ibn.fm/Yh65z). The company’s technology has been used alongside major brands, sports franchises and media organizations, demonstrating how gamification is increasingly becoming part of broader marketing strategies.

At the center of the company’s product portfolio is their Winfinite platform, which provides brands with a library of customizable games that can be deployed across websites, mobile devices, and digital campaigns. Rather than requiring organizations to build interactive experiences from scratch, the platform offers preconfigured templates that can be adapted for specific marketing objectives.

The appeal for marketers is efficiency. Campaigns can be launched quickly without extensive software development, allowing brands to integrate interactive content into existing marketing programs while collecting engagement data and encouraging repeat participation.

The games themselves are designed to be broadly accessible. Sports-themed contests, trivia experiences, arcade-style games and other casual formats are intended to appeal to a wide range of consumers. Participants can earn rewards ranging from discounts and digital incentives to larger prize packages, depending on the campaign structure.

Versus believes that connecting engagement directly to rewards creates stronger consumer interaction than conventional digital advertising. 

The company’s proprietary reward technology is another important part of the model. According to corporate materials, the platform has distributed prizes across multiple international markets, including the United States, the United Kingdom, India, China and Mexico. Rewards have included consumer electronics, travel packages, digital products and promotional offers. 

Managing reward programs across multiple jurisdictions presents regulatory challenges that many organizations prefer not to handle internally. Versus has developed systems designed to support compliance requirements while allowing brands to focus on campaign execution and customer engagement.

Beyond digital marketing, the company has also established a presence inside live-event environments. Its Filter Fan Cam product illustrates how audience participation is evolving within sports and entertainment venues. The platform uses facial tracking and augmented visual effects to place customized digital overlays on fans appearing on venue screens or broadcast feeds. These experiences can be branded, themed for specific events or sponsored by corporate partners.

The technology has been deployed at professional sporting events, including activations involving the Texas Rangers at Globe Life Field. For teams and venue operators, the product provides another way to enhance fan participation while creating additional sponsorship inventory.

The broader market opportunity remains substantial. According to data from Fortune Business Insights, the global gamification market was valued at approximately $6.3 billion in 2019 and is projected to expand significantly over the coming years, with estimates reaching nearly $90 billion by 2031.

Several trends are supporting that growth. Consumers increasingly expect interactive digital experiences. Mobile gaming has become mainstream across multiple age groups. At the same time, companies continue searching for methods to improve customer acquisition, retention and loyalty in a highly competitive digital marketplace.

Versus sits at the intersection of those trends. Its technology is designed to function across multiple channels, including websites, mobile applications, live events, broadcasts and streaming environments. That flexibility allows the company to address a range of customer needs without being tied to a single industry vertical.

The company has also demonstrated an ability to work across diverse sectors. Its partnerships have included sports organizations, media companies, entertainment brands and corporate marketers. Management believes those relationships validate the versatility of the platform and create opportunities for broader adoption.

Looking ahead, Versus is developing additional products intended to expand participation and engagement opportunities. Among them is Play Winfinite, a platform that would allow users to compete against friends or other players while earning rewards through a broader ecosystem of interactive games. The initiative reflects a larger industry trend toward combining entertainment, loyalty programs and digital engagement into unified experiences.

For more information, visit the company’s website at www.VersusSystems.com.

NOTE TO INVESTORS: The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VS

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, recognizes the current global dynamics regarding gold and silver pricing
• Although derivatives have enhanced liquidity in precious metals markets, they have also skewed pricing in the physical market
• CMX has adopted semi-annual financial reporting (“SAR”). This will help reduce the administrative and financial burden associated with quarterly reporting, allowing management to focus time and resources toward advancing the Clayton Silver Project

CMX (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, recognizes the current global dynamics regarding the pricing and trading of precious metals, including silver, and is prepping itself for any uncertainties that may arise. This follows the recent dramatic price movements for silver, the result of the clash of the old plumbing of physical precious metals supply with the non-stop machine of perpetual futures.

The new increased access to derivatives has shown potential to enhance liquidity and significantly improve hedging opportunities for market participants but also creates downsides. Most importantly, it introduces the risk of heightened leverage and skewed prices. This can lead to more frequent price squeezes along with cascading market movements (https://ibn.fm/yIoYU).

These dynamics can be seen in the price of silver thus far in 2026. In January, it began trading at around $72.70 an ounce, jumping to $116 by the end of the month. Come spring, this precious metal saw continued intraday swings, with the price jumping between the $80s to the low $60s (https://ibn.fm/CBOT0). While these prices have been tied to the price of gold, derivatives have played a key role in these swings, obscuring the more important long-term value of silver investment.

CMX believes this enhances the importance of moving forward with developing a silver resource on its 100%-owned Clayton Silver Project, located in the Bayhorse Mining District of central Idaho. Comprising a focused 1,028-acre land package, including 29 patented mining claims and two patented mill sites, the property has the potential to address the long-term growing demand for silver, delivering significant value to CMX and its various stakeholders.

CMX announced that it will adopt semi-annual financial reporting (“SAR”) in place of quarterly reports, with the fiscal year ending December 31^st. With this adjustment, CMX will reduce the administrative and financial burden associated with quarterly reporting. In addition, it will be consistent with the blanket order’s objective of providing reporting flexibility for venture issuers. With the time saved, management will be able to devote additional time and financial resources to advancing CMX’s Clayton Silver Project.

CMX will be exempt from filing first and third quarterly financial reports. CMX will file six-month interim financial reports within 60 days of June 30 and audited annual financial statements within 120 days of its year-end (https://ibn.fm/JsNFT).

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• The global drone market is growing, but the hardware sector of the market is becoming increasingly more commoditized. Basic flight capabilities are widely accessible, and drone hardware is easier and cheaper to get than ever before.
• As a result, software is quickly becoming the most valuable layer in the global drone market. It can add capabilities and features to basic drones without adding hardware costs.
• A company at the forefront of this industry is SPARC AI, which develops GPS-free target acquisition system and autonomous navigation software for both drones and edge devices.

In the drone industry, hardware is becoming increasingly commoditized. Many drone platforms now offer similar capabilities, and products from multiple manufacturers can execute basic flight operations with relative ease. As a result, drone hardware has become more accessible, affordable, and easier to source than ever before.

This shift is changing where value is created within the industry. Increasingly, the competitive advantage is no longer defined by the drone itself, but by the software that powers it. Advanced software can transform a drone from a simple aerial camera into an autonomous data-gathering platform capable of navigation, targeting, tracking, and mission execution with minimal human intervention.

As drone adoption continues to expand across commercial, industrial, and defense sectors, software platforms that enhance performance and unlock new capabilities, without requiring additional hardware investments, could play an increasingly important role in maximizing the technology’s potential.

One company operating at the forefront of this evolution is SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF). The company employs a software-first approach, developing next-generation GPS-denied target acquisition and autonomous navigation technologies for drones and other autonomous systems.

Its zero-signature technology delivers detection, tracking, and behavioral intelligence capabilities without relying on radar, lidar, or other bulky sensor systems. This allows defense, search-and-rescue, and commercial operators to function more effectively in environments where connectivity is limited and traditional navigation systems may be unreliable or unavailable.

SPARC AI’s technology utilizes known landmark coordinates to continuously calculate and correct a drone’s position, helping reduce navigational drift while improving operational accuracy.

The company recently announced a strategic partnership with Rate Manufacturing, a U.S.-based defense manufacturer, to integrate the company’s Overwatch platform into Rate’s Model-F multi-mission drone systems and future autonomous platforms. The collaboration combines Rate’s scalable drone production capabilities with SPARC AI’s software-based navigation and targeting technology, creating a solution designed for environments where GPS and GNSS signals may be degraded or denied. The partnership was unveiled during SOF Week in Tampa, one of the defense industry’s premier events, highlighting the growing interest in resilient drone technologies. Importantly, the agreement represents more than a single platform integration, it provides SPARC AI with a pathway into future drone programs while validating the company’s strategy of enhancing existing hardware through software rather than requiring costly sensor upgrades. As military and commercial operators increasingly seek affordable drones that can function in contested environments, software-driven solutions such as Overwatch could become a critical layer in next-generation autonomous systems.

Further strengthening its leadership team, SPARC AI also appointed Don Hilton as an Independent Non-Executive Director, effective immediately. As the company advances commercialization efforts and pursues growth opportunities within the defense technology sector, experienced board oversight can become increasingly valuable. Hilton’s background in financial management, governance, and strategic growth initiatives may help support the company as it scales operations, evaluates partnerships, and navigates the demands associated with becoming a larger and more mature organization.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

Date: June 16–17, 2026
Venue: Crown Perth, Australia

Investors, mining executives, and industry professionals are invited to two days of networking, collaboration, and strategic discussions at Mining News Select Australia 2026, taking place at Crown Perth, Australia. The highly anticipated event focuses on under-the-radar resource companies, highlighting opportunities within the rapidly evolving critical minerals and gold sectors.

Mining News Select serves as an interactive business platform where resource investors can engage directly with mining companies, gain visibility among industry icons, and explore investment opportunities shaping the future of the mining landscape. 

Attendees can participate in one-on-one meetings, expert panel discussions, and networking sessions designed to encourage meaningful conversations and facilitate valuable business relationships.

Why Attend?

• The event will host investor meetings where private and institutional investors seeking emerging opportunities can engage and establish long-term business relations.
• As demand for critical minerals continues to rise globally, discussions around resource development, supply chains, and investment trends will play important role throughout the conference.
• Mining News Select emphasizes interaction, bringing together private and institutional investors and selected mining projects.
• Attendees will also have access to networking opportunities and expert-led discussions that will positively influence investment decisions.

Global industry experts will share insights on broader trends currently influencing the mining sector. They will also explore resource strategies and investment plans in light of the growing geopolitical conditions, shifting supply chains, and the increasing demand for critical resources. The event also offers opportunities for participants to connect through structured meetings and expert-led sessions. Mining News Select seeks to create an environment where investors can gain a deeper understanding of potential projects while companies can engage with targeted audiences.

To learn more, please visit https://ibn.fm/Gb3xm.

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, has engaged the market-making services of ICP Securities to correct temporary imbalances in the supply and demand of the company’s listed shares
• ICP will support orderly trading, improve quote quality, and enhance liquidity with its proprietary market-making algorithm, as ESGold continues advancing toward production
• The engagement is part of ESGold’s efforts to ensure its market presence accurately reflects the progress it is making, including advancement toward production and an expanding shareholder base

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, has engaged ICP Securities (https://ibn.fm/FpiUd). Toronto-based ICP is an automated market maker and liquidity provider with a proprietary market-making algorithm, ICP Premium(TM), that improves liquidity and quote health. 

Under the agreement, ICP will provide ESGold with automated market-making services, including the use of its algorithm, in accordance with applicable laws and policies. As the designated automated market maker, ICP will facilitate smooth transactions of the company’s shares. Specifically, ICP will mainly help correct temporary imbalances in the supply and demand of ESGold’s listed shares.

“With the rise of algorithmic and high-frequency trading across the public markets, smaller public companies can be exposed to rapid trading activity that may amplify volatility, create short-term pricing inefficiencies, and cause the market to temporarily disconnect from the fundamentals of the business,” noted ESGold CEO, Gordon Robb.

“By engaging ICP, we are taking a proactive step to support more orderly trading, improve quote quality, and help mitigate temporary imbalances in the supply and demand of our shares,” he added.

The engagement comes amid positive developments, including the company’s continued advancement toward production and expansion of its shareholder base. For instance, ESGold recently announced a definitive agreement that would unlock a non-dilutive working capital facility of up to C$9 million to support near-term production and strengthen its operational and financial positioning (https://ibn.fm/cGbTE). The company, as a result, believes it is important for its market presence to reflect that underlying progress. Robb further explained that the agreement is part of ESGold’s move to enhance transparency and liquidity, and to create long-term value for its shareholders.

For more information about ESGold, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Earth Science Tech, a growing holding company focused on various aspects of the healthcare industry, reported a series of operational milestones in its fiscal year ended March 31, 2026, highlighted by expansion across its healthcare platform and continued cash-flow generation.
• Earth Science Tech repurchased and retired more than 6.9 million shares of common stock since fiscal Q1 2026, underscoring management’s focus on reducing share dilution in support of shareholder value.
• Key operating businesses, including DOConsultation, Villas Health and MOC Teledoc, are now cash-flow positive.
• Peaks Curative surpassed $2 million in revenue during the first week of fiscal Q4 2026, reflecting growth within the company’s health and wellness segment.
• Management emphasized that expansion initiatives were completed without adding debt to the balance sheet, maintaining a disciplined capital structure.
• Investors will have an opportunity to hear directly from management when CEO Giorgio R. Saumat presents at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17.

Earth Science Tech (OTC: ETST), a strategic healthcare-oriented holding company, has spent the past several years reshaping itself from a wellness-focused enterprise into a diversified holding company centered on healthcare, pharmaceutical compounding, telemedicine, real estate, and cash-flow-generating operating businesses. That transformation was a central theme of the company’s annual shareholder letter for the fiscal year ended March 31, 2026, where management highlighted operational progress, balance-sheet discipline, and an ongoing share repurchase strategy that has become a defining element of ETST’s capital allocation approach (https://ibn.fm/WX3CI).

In the letter, CEO and Chairman Giorgio R. Saumat described fiscal 2026 as a year in which the company strengthened the foundation for future growth while maintaining a debt-free approach to expansion.

Several milestones stood out. Among them was the continued development of Mister Meds, a Texas-based healthcare operation housed in a property previously acquired by the company. Management noted that the facility was built out and brought into operation without adding debt to the balance sheet.

The company also reported successful turnarounds of DOConsultation and Villas Health, both of which are now cash-flow positive according to management. These businesses play an important role within ETST’s broader healthcare ecosystem, which is designed to integrate telemedicine services, clinical support, prescription fulfillment, and pharmacy operations under a single corporate structure.

That vertical integration strategy remains a central part of the investment thesis surrounding the company. By controlling multiple stages of the patient journey, from consultation and diagnosis through prescription fulfillment and ongoing care, Earth Science Tech seeks to capture value across the healthcare continuum rather than relying on a single service line. Management believes this approach improves operational efficiency while increasing patient retention and lifetime value.

Another important development during the fiscal year was the relaunch of MyOnlineConsultation, also known as MOC Teledoc. The company rebuilt its proprietary technology infrastructure and repositioned the platform as a prescriber network. According to management, the operation has been cash-flow positive since its launch.

Meanwhile, Peaks Curative, another subsidiary within the ETST portfolio, recorded significant growth. Management reported that the business exceeded $2 million in revenue during the first week of the company’s fourth fiscal quarter, an achievement highlighted in the shareholder letter as evidence of increasing momentum across the health and wellness segment.

While operational performance attracted attention, the company’s capital allocation strategy is of particular interest. Earth Science Tech has consistently emphasized balance-sheet strength and shareholder value creation through share repurchases and share retirement programs.

During fiscal 2026, the company repurchased and retired 3,773,296 shares of common stock. In addition, management disclosed that another 3,150,392 shares had been retired during the current fiscal year-to-date period, bringing total repurchases and retirements since fiscal Q1 2026 to more than 6.9 million shares. For shareholders, reducing outstanding share count can help mitigate dilution while increasing ownership concentration among remaining investors.

The approach stands in contrast to many small-cap growth companies that frequently rely on equity issuance to fund expansion. ETST has repeatedly stressed that its acquisitions, operational improvements, infrastructure investments, and share repurchases have been completed without adding debt to the balance sheet. That emphasis on capital discipline appears throughout management’s communications.

In the shareholder letter, Saumat repeatedly referenced the company’s debt-free growth strategy, describing it as a key differentiator as ETST continues expanding its operating footprint.

Looking ahead, management indicated that the company will begin reporting results across two primary segments: Health/Wellness and Corporate/Other. The Health/Wellness segment is expected to remain the primary revenue driver and includes telemedicine, pharmacy-related activities, healthcare services, and associated operations. The Corporate/Other segment includes real estate development activities and broader asset management initiatives. The company also disclosed that three additional development properties are currently awaiting final permit approval, reflecting continued activity beyond healthcare operations.

Earth Science Tech also recently announced that Saumat will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17 at the Bellagio Resort & Hotel. The presentation will include a live question-and-answer session, and management will also be available for one-on-one meetings with investors throughout the event (https://ibn.fm/pAxrU).

“I look forward to meeting shareholders at the Planet Microcap Conference in Las Vegas on June 16th – 18th or at our annual shareholder meeting (date TBD – after we file our 10-K annual report),” Saumat said in conclusion of the letter to shareholders. “As we set our sights on the milestones ahead, we remain fiercely committed to transparency and to a relentless focus on maximizing shareholder value.”

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

Date:  June 16-17, 2026

Venue:  Crown Perth, Australia

Future of Mining Australia 2026 will bring together industry leaders, innovators, policymakers, and technology providers, in Perth, Australia, June 16–17, 2026, to discuss the next era of Mining. The event is positioned around the theme “Mining Smarter, Mining Better”. With the growing pressure to deliver more minerals and operate more efficiently, while maintaining a sustainable approach, the event focuses on practical solutions for enhancing efficiency, resilience, and long-term sustainability in mining operations.

Approximately 1,800 attendees are expected to attend this highly anticipated event, featuring over 900 mining executives, 100+ expert speakers, and more than 150 industry brands. Experts will share insights on the future of mining in over 70 sessions conducted over two days.

The event is hosted by Aspermont, a leading media service provider for the resource industries and businesses worldwide. As mining companies face growing pressure to reduce environmental impact while maintaining productivity, experts gather on this forum to discuss vital issues of automation, electrification, digital transformation, and workforce evolution.

Key themes of the Mining Australia series include:

• Technology Revolution
• Sustainability and ESG Practices
• Renewable-Energy Integration
• Circular Economy and Recycling
• Community Engagement and Social Inclusion
• Responsible Mineral Supply Chains
• Regulatory and Policy Landscape
• Investing in Innovation

The conference will explore how mining businesses can adapt to changing market conditions and evolving global demands. Topics of discussion include artificial intelligence, safety innovations, decarbonization strategies, and technologies supporting critical minerals development.  

Future of Mining Australia 2026 serves as a phenomenal platform for collaboration and knowledge sharing, helping industry stakeholders develop strategies that strengthen operational performance while preparing for the next generation of mining challenges.  

To learn more, please visit https://ibn.fm/5389U.

• The corporate DAT movement has gained visibility as public companies increasingly treat bitcoin and other digital assets as strategic balance-sheet holdings rather than short-term speculative instruments
• MindWave provides a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies and transparent reporting systems.
• The company’s institutional positioning is strengthened by its live bitcoin treasury activity.

As bitcoin moves deeper into corporate finance, the central question for many companies is no longer whether digital assets belong on the balance sheet but rather how they can be held, reported and deployed responsibly. MindWave Innovations (NYSE American: APUS) is positioning itself around that challenge as a digital asset and technology company focused on institutional-grade treasury infrastructure, combining insured custody solutions, AI-enabled yield strategies and transparent reporting systems for the digital asset economy.

The corporate Digital Asset Treasury, or DAT, movement has gained visibility as public companies increasingly treat bitcoin and other digital assets as strategic balance-sheet holdings rather than short-term speculative instruments. Research has described the DAT market as an emerging category of companies built around digital asset accumulation and treasury strategy, while earlier public-company examples such as Strategy and Metaplanet helped popularize bitcoin-centered treasury models.

That momentum has also exposed the practical barriers facing corporate finance teams. A digital asset treasury strategy requires more than buying bitcoin. Companies must address custody, accounting treatment, tax considerations, reconciliation, transaction approvals, volatility, audit controls and more. For example, BitGo’s crypto treasury management guidance notes that treasury management includes custody, key management, approvals, accounting, tax, audit support and counterparty controls, while Cozen O’Connor has emphasized the role of boards and management teams in aligning digital asset decisions with risk management and disclosure obligations.

Regulatory and accounting developments are also helping shape the environment for more institutional participation. The Financial Accounting Standards Board’s ASU 2023-08 requires certain crypto assets to be measured at fair value each reporting period, with changes reflected in net income, creating a clearer accounting framework for companies that hold assets such as Bitcoin. In addition, SEC’s Staff Accounting Bulletin No. 122 rescinded earlier SAB 121 guidance on safeguarding crypto assets, further signaling that digital asset accounting and custody rules continue to evolve.

MindWave’s platform is designed to respond to that institutional gap. MindWave provides a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies and transparent reporting systems. That combination is important because corporate adoption depends not only on asset exposure but also on the ability to demonstrate that treasury activity is documented and aligned with the expectations of directors, auditors and shareholders.

The company’s broader MindWaveDAO platform extends that treasury model into a blockchain-enabled ecosystem. MindWaveDAO describes itself as a decentralized autonomous organization building financial infrastructure that combines traditional finance security and compliance with blockchain transparency and efficiency. Its ecosystem is powered by the NILA token, which the platform says enables staking and access to financial products across the network.

A notable component of the ecosystem is MindWaveDAO’s Real-World Asset (RWA) framework, which is designed to bring traditional assets onto blockchain rails through tokenization. According to the company, the platform seeks to connect real-world value with decentralized finance by enabling assets such as real estate, commodities and other income-generating investments to participate in a more transparent and accessible digital environment. The initiative reflects a broader industry trend toward tokenized assets, a market many analysts view as one of the most significant long-term opportunities within blockchain-based finance.

By incorporating RWA infrastructure alongside digital asset treasury services, MindWaveDAO is positioning its ecosystem around both crypto-native and traditional asset classes. That approach expands the platform’s potential utility beyond bitcoin treasury management, creating additional pathways for yield generation, capital deployment and asset participation within the broader network.

A central component of the platform is the MindWave AI Yield Engine, which the company describes as a self-learning system that analyzes digital asset market data, identifies opportunities and mitigates risks in real time. For corporations considering bitcoin treasury strategies, this type of structure points to a broader evolution in DAT models: the move from passive holding toward actively managed infrastructure intended to support risk controls, yield generation and capital efficiency.

MindWaveDAO also presents NILA as a utility layer within the ecosystem. The company’s NILA token page states that NILA functions as the native gas token for its MindChain Layer 2 network and is used for staking tied to yield generated by the AI-powered engine. The same page describes NILA as deeply integrated into the MindWaveDAO ecosystem, connecting transaction utility, staking and platform participation.

The company’s institutional positioning is strengthened by its live bitcoin treasury activity. In December 2025, Apimeds Pharmaceuticals and MindWave Innovations announced the closing of up to $100 million PIPE financing and the activation of 1,000 bitcoin to power an AI-driven yield generation strategy. That announcement is significant because it frames MindWave’s model as more than a conceptual platform; it identifies an operating bitcoin position connected to a stated treasury and yield strategy.

The public-company structure also matters. Apimeds announced its merger with MindWave Innovations as a transaction combining Apimeds’ biotechnology portfolio with MindWave’s AI-driven bitcoin treasury, digital asset yield generation and NILA-powered ecosystem. In the DAT market, that type of public-market access can provide investors with exposure to digital asset treasury strategies through traditional equity channels, while also bringing the scrutiny and disclosure expectations associated with public companies.

For institutional adopters, the most important value proposition may be execution. Companies interested in holding bitcoin must satisfy internal controls, satisfy board oversight, manage custody risk, prepare financial statements and explain strategy to investors. MindWave’s model speaks directly to those needs by pairing custody and reporting infrastructure with AI-driven treasury functions and tokenized ecosystem utility.

As the DAT market matures, the winning models are likely to be those that can bridge crypto-native opportunity with institutional discipline. MindWave is attempting to occupy that middle ground by connecting public-market structure, live bitcoin holdings, tokenized real-world asset infrastructure, AI-driven yield capabilities, custody-focused controls and NILA-based ecosystem participation. In doing so, the company reflects the next stage of corporate bitcoin treasury adoption: not simply adding bitcoin to the balance sheet but building the infrastructure needed to manage it at scale.

For more information, visit the company’s website at www.MindWaveDAO.com

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• VERAXA is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications.
• The company’s proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity.
• Through its focus on ADCs and TCEs, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.
• Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (“RICs”) and antibody-oligonucleotide conjugates (“AOCs”).

VERAXA Biotech has successfully concluded a business combination with Voyager Acquisition Corp. (NASDAQ: VACH) and began trading on the NASDAQ Capital Market under the ticker symbol ‘VRXA’ on June 11, 2026.

VERAXA Biotech (NASDAQ: VRXA) is a biotechnology company focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles.

The company is building a pipeline that includes dual-targeting antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”) predominantly based on its patented BiTAC concept. This concept is designed to improve the precision, safety, and effectiveness of cancer treatments. Through its focus on potentially first-in-class conditionally active ADC and TCE platforms, VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.

The biopharma industry is increasingly focusing on enhancing the therapeutic window of next-generation ADCs and TCEs by refining their tumor selectivity, conditional activation, and dose optimization. This shift—driven by clinical data demonstrating improved safety profiles and the potential for higher, more effective dosing—reflects a broader movement toward safer, more tolerable, and patient-friendly cancer therapies, ultimately aiming to unlock the full potential of these modalities especially in solid tumor settings.

VERAXA is headquartered in Zurich, Switzerland, with its R&D hub located in Heidelberg, Germany.

Pipeline

Central to VERAXA’s strategy is the application of its proprietary technology concept BiTAC (Bi-targeted Tumor-Associated Cytotoxicity), which enables the generation of conditionally active, AND-gated therapeutic candidates that precisely target cancer cells while leaving healthy cells intact. VERAXA is currently advancing a pipeline of early development programs with a focus on solid tumors. The most advanced program, a BiTAC-TCE targeting EpCAM and another tumor antigen has recently entered preclinical development. More detailed information on these early-stage assets is expected to emerge in the months following the NASDAQ listing.

VX-A901

VX-A901, a clinical-stage, monoclonal antibody therapy targeting FLT3 for the treatment of acute myeloid leukemia (“AML”) is currently VERAXA’s most-advanced program.

The antibody is designed to enhance antibody-dependent cellular cytotoxicity (“ADCC”), a mechanism that helps direct immune cells against cancer cells.

The program is intended to address the need for additional treatment options for elderly AML patients or patients who are not eligible for intensive chemotherapy and stem cell transplantation. VX-A901 has a distinct and complementary mechanism of action, independent of the patient’s FLT3 mutation status and could be combined with first-line therapy. Phase I results show that VX-A901 was safe and well tolerated in AML patients, with promising signs of monotherapy efficacy observed in heavily pre-treated patients. VERAXA has decided to out-license the future development and commercialization of the program due to the increasing focus on AND-gated modalities for the treatment of solid tumor indications.

BiTAC Platform

BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) is VERAXA’s proprietary underlying concept of a new generation of dual-targeting antibodies with enhanced safety and efficacy characteristics. Unlike conventional bispecific antibodies that combine two target specificities within a single molecule, BiTAC splits the therapeutic candidate into two complementary molecules.

Any therapeutic effect is activated only when both molecules localize on the same tumor cell. VERAXA is applying this architecture to both TCE and ADC development programs with the goal of improving tumor selectivity, reducing damage to healthy tissues and thereby expanding the safety-to-efficacy ratio (therapeutic index).

Initial data from VERAXA’s most advanced BiTAC-TCE program were presented at the recent American Association for Cancer Research (“AACR”) Annual Meeting 2026 in San Diego, CA.  VERAXA’s BiTAC-TCE candidate performed as intended, attacking cancer cells featuring both target molecules while sparing cells expressing just one of these targets. In vivo data demonstrated a superior safety profile and matching efficacy compared to a conventional TCE, pointing to the possibility of a significantly improved therapeutic index.

Other ADC Technologies

VERAXA has developed a suite of technologies based on their proprietary biorthogonal click chemistry to innovate industry-leading ADC therapeutics. This includes a proprietary hydrophilic payload-linker platform, utilizing tumor-selective linkers, and glycan engineering-based click conjugation to site-specifically attach the payload to the antibody. Furthermore, the payload platform includes a proprietary prodrug approach of highly potent toxins, also based on tumor-selective activation. Through the combination of these technologies, VERAXA’s ADCs display favorable pharmacokinetics and offer an opportunity to enhance the safety-to-efficacy ratio of current ADCs. Initial data from VERAXA’s most advanced ADC program were presented at the recent American Association for Cancer Research (“AACR”) Annual Meeting 2026 in San Diego, CA.

Market Opportunity

VERAXA’s development strategy is centered on antibody-drug conjugates and bispecific T cell engagers, two areas of oncology therapeutics that have attracted significant industry attention due to their potential to improve treatment precision, efficacy, and safety. As the company advances programs across both categories, it is operating within markets that are expected to experience substantial long-term growth and deal activity.

The global antibody-drug conjugates market was valued at approximately $12.26 billion in 2024 and is projected to reach approximately $32.11 billion by 2033, according to Grand View Research, representing a compound annual growth rate of 10.49% from 2025 through 2033. The firm attributes this growth to increasing cancer prevalence and growing demand for targeted therapies designed to improve efficacy while reducing systemic toxicity.

According to Precedence Research, the global bispecific antibodies market is estimated at approximately $17.99 billion in 2025 and is projected to reach approximately $603.13 billion by 2035, representing a compound annual growth rate of 42.08% from 2025 through 2034.

Leadership Team

Christoph Antz, Ph.D., Chief Executive Officer and Co-Founder, is an experienced life sciences executive and former venture capital manager with expertise spanning drug development, diagnostics and scientific instrumentation. Prior to co-founding VERAXA, he served as managing director of Acousia Therapeutics and Luxendo, where he helped lead companies focused on inner-ear therapeutics and advanced microscopy technologies.

Torsten Bürgermeister, Chief Financial Officer, brings more than 20 years of finance and business development experience across life science and technology companies. Before joining VERAXA, he held leadership positions with Molecular Health, BASF Pharma, Techem Energy Services and Colt Telecom, and holds a diploma in business administration from DHBW Mannheim.

Rick Austin, Ph.D., Chief Scientific Officer, has extensive experience in oncology drug discovery and T-cell engager development. Prior to joining VERAXA, he served as vice president of research at Harpoon Therapeutics and previously held scientific leadership positions at Amgen and Tularik, contributing to multiple tumor immunology programs, IND filings and first-in-human studies while authoring more than 25 peer-reviewed publications and contributing to 12 issued patents.

Heinz Schwer, Ph.D., MBA, Chief Business Officer, is a serial biotechnology entrepreneur and former venture capital investor. Before joining VERAXA, he served as general partner at EMBL Ventures and previously held chief executive roles at ViraTherapeutics, Lanthio Pharma and Sloning BioTechnology, each of which was subsequently acquired by larger industry participants.

Christoph Erkel, Ph.D., Vice President of Research & Development, has more than 15 years of experience in early-stage drug discovery, with expertise spanning discovery, engineering, and preclinical development of antibodies. Prior to VERAXA, he held several positions of increasing responsibility in R&D at MorphoSys AG, where he led immuno-oncology programs focused on conditionally active T-cell engagers for the treatment of solid and hematologic tumors.

For more information, visit the company’s website at www.VERAXA.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA https://ibn.fm/VRXA

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.

• Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance.
• The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies.
• Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances.
• Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph(TM) causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.
• Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a clinical-stage oncology company focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. The company is leading the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance. Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.

The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions, research partnerships and manufacturing initiatives, including the acquisition of Inka Health Corp. and its SynoGraph(TM) platform, a proprietary causal AI technology designed to support predictive oncology modeling and evidence generation. The company has also established relationships across pharmaceutical development, analytics and clinical research environments as it advances its broader oncology ecosystem.

Alongside its therapeutic and AI-focused initiatives, Onco-Innovations continues to advance manufacturing, regulatory and preclinical programs intended to support future clinical studies. The company’s stated mission is to develop cutting-edge therapies that improve patient outcomes and bring hope in the fight against cancer.

Onco-Innovations Ltd. is headquartered in Calgary, Alberta.

Products and Development Pipeline

Onco-Innovations is advancing ONC010(TM), a nanoparticle-encapsulated drug candidate built around the company’s proprietary PNKP inhibitor technology. PNKP plays a central role in repairing damaged DNA, and the company’s approach is designed to disrupt these repair mechanisms, resulting in the accumulation of DNA damage within cancer cells.

PNKP represents a novel drug target, with PNKP inhibitors emerging as a new and distinct class of DNA Damage Response cancer therapies. Inhibition of PNKP kills tumor cells by sensitizing them to radiation and DNA-damaging chemotherapies, and by exploiting tumors with certain DNA repair defects. The company’s lead program is initially focused on exploiting these repair vulnerabilities in biomarker-selected solid tumors and hematologic cancers, with future development incorporating combinations with chemotherapy or radiotherapy. In preclinical testing, PNKP inhibition is active in colorectal cancer, lung cancer, breast cancer, prostate cancer, lymphoma, leukemia, and ovarian cancer.

Five patents protect the company’s PNKP technology platform and related innovations.

A key component of ONC010 is its proprietary nanoparticle delivery system, which combines the active pharmaceutical ingredient A83B4C63 with a polymer-based micellar carrier designed to improve drug delivery to tumors. The platform was developed to address historical toxicity and delivery challenges associated with DNA Damage Response inhibitors by extending circulation time, enhancing tumor accumulation and limiting off-target exposure. Preclinical studies have demonstrated tumor reduction, increased median survival and favorable toxicity profiles in animal models, supporting the company’s ongoing efforts to advance the program toward first-in-human clinical studies.

To support clinical advancement, Onco-Innovations continues to execute an integrated Chemistry, Manufacturing and Controls (“CMC”) program in collaboration with Dalton Pharma Services while conducting pharmacokinetic and biodistribution studies with Nucro-Technics. Recent activities have included analytical method development, impurity profiling, polymer characterization, manufacturing scale-up, formulation development and validation work designed to support IND-enabling studies and future clinical readiness. The company has also established operational infrastructure in Australia to support planned Phase I development activities and regulatory progression through the Therapeutic Goods Administration pathway.

In addition to its therapeutics platform, Onco-Innovations has expanded its capabilities through the acquisition of Inka Health Corp. and its SynoGraph(TM) platform. The company describes SynoGraph(TM) as a proprietary causal AI platform designed to support prediction of oncology clinical trial outcomes, treatment efficacy, safety and adverse events through the integration of real-world data, clinical evidence and molecular insights. The platform is intended to support patient stratification, trial design, translational decision-making and evidence generation while helping reduce the time, cost and risk associated with oncology drug development. Through Inka Health, Onco-Innovations has announced collaborations involving AstraZeneca, GlaxoSmithKline and other strategic partners focused on predictive modeling, real-world evidence and AI-enabled oncology research.

Market Opportunity

Onco-Innovations is targeting opportunities across the oncology, precision medicine and DNA Damage Response (“DDR”) therapy markets. Company materials state that DDR inhibitors represented more than $7 billion in global sales during 2025, reflecting growing interest in therapies designed to disrupt cancer cells’ ability to repair damaged DNA. The company believes PNKP inhibitors represent an emerging class within the broader DDR landscape, positioning Onco-Innovations within a rapidly evolving segment of oncology drug development.

The company’s lead therapeutic program will evaluate PNKP inhibition in biomarker-selected solid tumors and hematologic cancers. Beyond monotherapy, Onco-Innovations anticipates combining its PNKP inhibitor with chemotherapy and radiation. Onco-Innovations is also actively engaged in extending its PNKP inhibitor technology and related intellectual property, and in expanding its portfolio of cancer therapies.

According to company materials, the global oncology market is projected to approach approximately $500 billion by 2032, representing projected growth of 131% over a 10-year period. The company also cites projections indicating that global cancer cases may rise by 47% by 2040, while the broader oncology market is expected to grow at a compound annual growth rate of 8.9%. A Grand View Research report projects the global precision medicine market could reach approximately $405.1 billion by 2033, growing at a compound annual growth rate of 16.99% from 2026 through 2033.

Leadership Team

Thomas O’Shaughnessy, Chief Executive Officer, brings more than 25 years of experience across healthcare, life sciences, strategy and operations. A former partner at Deloitte Canada, he previously led national health industry growth initiatives and digital health programs. He is also the founder of Carnarvon Strategies and serves as a senior advisor focused on healthcare and life sciences strategy, operational execution and value creation.

Nico Mah, Chief Financial Officer and Corporate Secretary, is a Chartered Professional Accountant with experience in auditing and public accountancy. Prior to joining Onco-Innovations, he worked at PricewaterhouseCoopers LLP from 2015 through 2023, progressing from associate to manager while supporting audit, tax and consulting activities.

Dr. Islam Mohamed, Chief Medical Officer, oversees the company’s clinical strategy, including protocol development, medical oversight and regulatory engagement activities. His role includes supporting IND-enabling initiatives and helping guide the advancement of the company’s PNKP inhibitor program into early-stage clinical development while maintaining relationships with investigators, regulators and oncology stakeholders.

Stephen M. Novak, Chief of Research and Development, leads the company’s development operations across manufacturing, preclinical activities, Chemistry, Manufacturing and Controls programs and global program execution. His background includes advancing therapeutic programs through multiple stages of development with experience in GMP and GLP oversight, regulatory readiness and coordination with CRO and CDMO partners.

For more information, visit the company’s website at OncoInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF